ALK and non-small cell lung carcinoma: The EML4-ALK fusion gene is one of the most desirable molecular targets for patients with ALK-rearranged NSCLC because there are several specific tyrosine kinase inhibitors (TKIs) available for treatment1, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib6,7.